Open Label Icatibant home study in Hereditary Angioedema (IRB# 38489)
- Timothy Craig, D.O., Division of Pulmonary, Allergy and Critical Care Medicine
Open-Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema.
Penn State Milton S. Hershey Medical Center
Study director: Timothy Craig, D.O.
For more information: call Crystal Rhoads, 717-531-4513